Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QFQD | ISIN: US3441741077 | Ticker-Symbol:
NASDAQ
31.03.25
21:39 Uhr
3,670 US-Dollar
+0,130
+3,67 %
1-Jahres-Chart
FOGHORN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
FOGHORN THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur FOGHORN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiFoghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting25- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical...
► Artikel lesen
20.03.Foghorn Therapeutics scales down ATM stock offering to $100M1
20.03.Foghorn Therapeutics Inc. - 8-K, Current Report 1
07.03.H.C. Wainwright maintains $13 target on Foghorn shares1
06.03.Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook58First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary...
► Artikel lesen
06.03.Foghorn Therapeutics Inc. - 8-K, Current Report-
03.02.Foghorn Therapeutics Inc. - 8-K, Current Report-
30.01.Foghorn Therapeutics a new buy at B Riley on tumor fighting technology3
FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln
24.01.Foghorn Therapeutics files for mixed shelf offering5
24.01.Foghorn Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans-
24.01.Foghorn Therapeutics Inc. - 8-K, Current Report-
13.01.Foghorn Therapeutics Inc. - 8-K, Current Report-
02.01.Foghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest Update2
30.12.24Foghorn Therapeutics Inc. - 8-K, Current Report-
16.12.24Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower1
16.12.24Foghorn gives up on sole wholly owned clinical asset after phase 1 leukemia failure2
16.12.24Foghorn shifts focus from AML drug FHD-2862
16.12.24Foghorn verlagert Fokus von AML-Medikament FHD-2866
16.12.24Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities126Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy...
► Artikel lesen
16.12.24Foghorn Therapeutics Inc. - 8-K, Current Report-
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1